Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 23Carcinoma, Non-Small-Cell Lung 21Fallopian Tube Neoplasms 16Ovarian Neoplasms 14Triple Negative Breast Neoplasms 9Lung Neoplasms 9Brenner Tumor 9Breast Neoplasms, Male 9Adenocarcinoma of Lung 9Adenocarcinoma, Bronchiolo-Alveolar 8Unspecified Adult Solid Tumor, Protocol Specific 7Endometrial Neoplasms 7Neoplasm Metastasis 6Carcinoma, Ovarian Epithelial 6Melanoma 5Pancreatic Neoplasms 4Uterine Cervical Neoplasms 3Esophageal Neoplasms 3Carcinoma, Transitional Cell 3Adenocarcinoma Of Esophagus 3Urinary Bladder Neoplasms 2Platinum-Refractory Fallopian Tube Carcinoma 2Oropharyngeal Neoplasms 2Endometrial Adenocarcinoma 2Carcinoma 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Thyroid Carcinoma, Anaplastic 1Testicular Neoplasms 1Stomach Neoplasms 1

Interventions

Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hemoptysis × Taxes × Clear all
NCT00387374 2013-01-17

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hemoptysis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡